Wang Lian, Fan Jin, Zheng Linli, Chen Lingmin
Department of Respiratory and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Pharmacol. 2022 Jul 19;13:932688. doi: 10.3389/fphar.2022.932688. eCollection 2022.
Skin and soft tissue infections (SSTIs) are among the most common infections worldwide. They manifest in a variety of forms, such as erysipelas, cellulitis, and necrotizing fasciitis. Antibiotics are the significant method for clinical treatment of SSTIs. This study reported a methodology framework to determine the efficacy and safety of iclaprim in treatment of SSTIs. We will search the PubMed, EMbase, CNKI, WanFang Data, VIP, and ClinicalTrials.gov from their inception to June 2022 for randomized controlled trials and cohort studies on iclaprim with SSTIs. Two authors will independently screen the eligible studies, assess the quality of the included papers, and extract the required information. Randomized controlled trials will be assessed using the Cochrane risk-of-bias tool. The Newcastle-Ottawa Scale will be used to evaluate observational studies. The quality of the evidence will be evaluated using the Grading of Recommendations Assessment Development and Evaluation system. RevMan 5.3 will be used for the data synthesis and quantitative analysis. This study will provide the clinicians with more high-quality evidence to choose iclaprim for patients with SSTIs. This systematic review and meta-analysis will be based on published data, so ethical approval is not necessary. The results of this meta-analysis will be published in a peer-reviewed journal.
皮肤和软组织感染（SSTIs）是全球最常见的感染之一。它们有多种表现形式，如丹毒、蜂窝织炎和坏死性筋膜炎。抗生素是SSTIs临床治疗的主要方法。本研究报告了一种确定伊克拉普明治疗SSTIs疗效和安全性的方法框架。我们将检索PubMed、EMbase、中国知网、万方数据、维普资讯和ClinicalTrials.gov，从其创建至2022年6月，查找关于伊克拉普明治疗SSTIs的随机对照试验和队列研究。两名作者将独立筛选符合条件的研究，评估纳入论文的质量，并提取所需信息。随机对照试验将使用Cochrane偏倚风险工具进行评估。纽卡斯尔-渥太华量表将用于评估观察性研究。证据质量将使用推荐分级评估、制定和评价系统进行评估。RevMan 5.3将用于数据合成和定量分析。本研究将为临床医生提供更多高质量证据，以便为SSTIs患者选择伊克拉普明。本系统评价和荟萃分析将基于已发表的数据，因此无需伦理批准。本荟萃分析的结果将发表在同行评审期刊上。
